Combining Antiandrogens with Immunotherapy for Bladder Cancer Treatment.

ABSTRACT:

Background

Men are three to four times more likely to be diagnosed with bladder cancer (BCa) than women, who often have more aggressive tumors. Intravesical bacillus Calmette-Guerin (BCG) for non-muscle-invasive bladder cancer (NMIBC) is one of the first immunotherapies, with use of immune checkpoint inhibitors for BCa immunotherapy expanding. Sex hormones, and notably androgens, might impact the outcome of these therapies.

Objective

To understand immunological sex differences in BCa and investigate androgen receptor (AR) inhibition as a novel strategy to improve the response to BCa immunotherapy.

Design setting and participants

Human NMIBC tumors were freshly collected following transurethral resection. In vivo studies used the subcutaneous MBT-2 BCa model in

SUBMITTER: Besancon M 

PROVIDER: S-EPMC9557088 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature